Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Vascular smooth muscle RbFox2 regulates the cytoskeleton and arterial stiffness by a RhoBTB1/Cullin-3 mechanism
Gaurav Kumar, Nisita Chaihongsa, Daniel T. Brozoski, Daria Golosova, Ibrahim Vazirabad, Ko-Ting Lu, Kelsey K. Wackman, Ravi K. Singh, Curt D. Sigmund
Gaurav Kumar, Nisita Chaihongsa, Daniel T. Brozoski, Daria Golosova, Ibrahim Vazirabad, Ko-Ting Lu, Kelsey K. Wackman, Ravi K. Singh, Curt D. Sigmund
View: Text | PDF
Research Article Cardiology Vascular biology

Vascular smooth muscle RbFox2 regulates the cytoskeleton and arterial stiffness by a RhoBTB1/Cullin-3 mechanism

  • Text
  • PDF
Abstract

The RhoBTB1/Cullin-3 (CUL3) pathway in smooth muscle cells (SMCs) controls the ubiquitination and proteasomal degradation of target proteins that regulate vasodilation, vasoconstriction, and the actin cytoskeleton and, through this, blood pressure (BP) and arterial stiffness. Using proximity labeling coupled with mass spectrometry in A7R5 SMCs, we identified proteins that bound to the C-terminal half of RhoBTB1, which functions as an adaptor to deliver substrates to CUL3. We examined the physiological relevance of one of these substrates, RbFox2. Coimmunoprecipitation validated the interaction of RbFox2 with RhoBTB1. RbFox2 expression was elevated in response to inhibition of the ubiquitination-proteasomal pathway, CUL3 deficiency, and RhoBTB1 inhibition by either siRNA or angiotensin II (ANG). RbFox2 was ubiquitinated in a RhoBTB1- and CUL3-dependent manner, suggesting its regulation through the RhoBTB1/CUL3-dependent ubiquitin-proteasome pathway. Inhibition of RbFox2 impaired the actin cytoskeleton in A7R5 cells and in primary SMCs from RbFox2fl/fl mice and decreased the levels of globular and filamentous actin. ANG increased BP and arterial stiffness of RbFox2fl/fl mice, but the progression of arterial stiffness was halted after SMC-specific RbFox2 deletion despite a continued rise in BP. We conclude that RhoBTB1 and RbFox2 are important regulators of arterial stiffness through a mechanism that influences cytoskeletal integrity.

Authors

Gaurav Kumar, Nisita Chaihongsa, Daniel T. Brozoski, Daria Golosova, Ibrahim Vazirabad, Ko-Ting Lu, Kelsey K. Wackman, Ravi K. Singh, Curt D. Sigmund

×

Figure 11

Role of RbFox2 and Actn1 in primary human aortic SMCs.

Options: View larger image (or click on image) Download as PowerPoint
Role of RbFox2 and Actn1 in primary human aortic SMCs.
(A) Immunoblot de...
(A) Immunoblot demonstrating the regulation of RbFox2 by CUL3-dependent ubiquitin-proteasome pathway in human aortic SMCs (HASMCs) treated with MLN4924 (1 µM) or MG132 (10 µM) for 24 hours. Hsp90 was used as a loading control. The experiment was performed with 3 independent samples and is quantified below. Data represent mean ± SEM; *P < 0.05 by 2-tailed t test; N = 3 each. (B) Relative levels of RbFox2 and RhoBTB1 in HASMCs transfected with scrambled control and siRNA targeting RhoBTB1 for 72 hours. Hsp90 was used as an internal control for protein loading. Data are quantified below and represent mean ± SEM; *P < 0.05 by 2-tailed t test; N = 3. (C) Immunoblot measuring the expression of RbFox2 in response to ramped increases in ANG treatment (1.0, 2.5, 3.5 μM) of HASMCs. Data are quantified and represent mean of N = 2 samples. Immunoblots were probed with indicated antisera. Molecular weight markers are translated from original blots. (D) Real-time RT-PCR of ACTN1 expression in response to scrambled siRNA (Control) and siRNA targeting ACTN1 in HASMCs. Data represent mean ± SEM; *P < 0.05 by 2-tailed t test; N = 3 each. (E) Phalloidin staining (green) in HASMCs following ACTN1 siRNA transfection (72 hours) compared with scrambled control. Images represent fields from duplicate independent experiments. Scale bar: 10 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts